Nazak Michael Adrian 4
4 · Aridis Pharmaceuticals, Inc. · Filed Feb 22, 2021
Insider Transaction Report
Form 4
Nazak Michael Adrian
Chief Financial Officer
Transactions
- Exercise/Conversion
Stock Options
2021-02-18+20,000→ 80,000 totalExercise: $7.84Exp: 2031-02-18→ Common Stock (20,000 underlying)
Footnotes (1)
- [F1]The stock options vest in equal installments over 48 months, beginning on February 1, 2021.